GIS:ETR
Gilead Sciences, Inc
131,78 €
arrow_downward
-0,84%(-1,12) 1D
14 қаз., 10:05:06 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIS...
Open
131,86 €
High
131,90 €
Low
131,78 €
Mkt. cap
183,41 млрд
Avg. vol.
805,00
Volume
15,00
52-wk high
136,24 €
52-wk low
98,96 €
No. of employees
17 мың
Open
131,86 €
High
131,90 €
Low
131,78 €
Mkt. cap
183,41 млрд
Avg. vol.
805,00
Volume
15,00
52-wk high
136,24 €
52-wk low
98,96 €
No. of employees
17 мың
News stories
From web sources and news partners
MarketBeat
·
1 сағат бұрын
Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC
ad-hoc-news.de
·
2 сағат бұрын
Gilead Sciences consensus target USD 160.07: stock pre-market at EUR 131.97, minus 0.70 percent
Benzinga
·
10 сағат бұрын
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Insider Monkey
·
1 күн бұрын
Can Gilead (GILD) Stock Continue Rising in 2027?
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 мың
Founded1987 ж. 22 мау.
HeadquartersFoster City, Калифорния, Америка Құрама Штаттары
Sector-
Websitegilead.com